Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers | Haematologica

Francesco Zaja; Stefano De Luca; Umberto Vitolo; Lorella Orsucci; Alessandro Levis; Flavia Salvi

首页> 外文期刊>Haematologica >Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers | Haematologica

【24h】

Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers | Haematologica

机译：来那度胺和地塞米松治疗复发/难治性套细胞淋巴瘤的临床疗效及对微环境和新血管生成生物标志物的影响血液学

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background Preclinical studies have highlighted the activity of lenalidomide in mantle cell lymphoma and its anti-proliferative synergy with dexamethasone.

机译：背景临床前研究强调来那度胺在套细胞淋巴瘤中的活性及其与地塞米松的抗增殖协同作用。

著录项

来源
《Haematologica》 |2012年第3期|共7页
作者
Francesco Zaja; Stefano De Luca; Umberto Vitolo; Lorella Orsucci; Alessandro Levis; Flavia Salvi;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma | Haematologica [J] . Wolfgang Lamm, Hannes Kaufmann, Markus Raderer, Haematologica . 2011,第7期

机译：硼替佐米联合利妥昔单抗和地塞米松是复发和化疗难治性套细胞淋巴瘤患者的有效方案血液学
2. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: A phase 1/2 clinical trial [J] . WangM., FayadL., Wagner-BartakN., The lancet oncology . 2012,第7期

机译：来那度胺联合利妥昔单抗治疗复发或难治性套细胞淋巴瘤的患者：1/2期临床试验
3. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): Report of a phase I/II trial [J] . HopfingerG., N?sslingerT., LangA., Annals of hematology . 2014,第3期

机译：来那度胺联合伏立诺他和地塞米松治疗复发/难治性外周T细胞淋巴瘤（PTCL）：I / II期试验报告
4. CLINICAL EVALUATION OF A CD40-ACTIVATED B CELL VACCINE TO PREVENT LYMPHOMA RELAPSE INDOGS [C] . Nicola J. Mason Conference of the American College of Veterinary Internal Medicine . 2014

机译：CD40活化B细胞疫苗的临床评价，以防止犬淋巴瘤复发
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers [O] . Francesco Zaja, Stefano De Luca, Umberto Vitolo, 2012

机译：来那度胺和地塞米松挽救治疗复发/难治性套细胞淋巴瘤的临床结果及其对微环境和新血管生成生物标志物的影响
7. Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers [O] . Zaja, Francesco, De Luca, Stefano, Vitolo, Umberto, 2011

机译：来那度胺和地塞米松挽救治疗复发/难治性套细胞淋巴瘤的临床结果及其对微环境和新血管生成生物标志物的影响
8. Innate Anti-Breast Cancer Activity of -T cells: A Novel Biological and Clinical Approach to the Treatment of Relapsed or Refractory Breast Cancer [R] . Lopez, R. D. 2009

机译：T细胞的先天性抗乳腺癌活性：一种治疗复发或难治性乳腺癌的新型生物和临床方法

Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers | Haematologica

摘要

著录项

相似文献

相关主题

期刊订阅